"Piece by piece scientific advances are paving the way to the end of the AIDS epidemic," said Michel Sidibe, Executive Director of the Joint UN Program on HIV/AIDS (UNAIDS), welcoming the findings that an antiretroviral, taken daily, can reduce the risk of HIV infection by nearly half in HIV-negative man and women who inject drugs.
"The full potential of antiretroviral therapy in keeping people alive and well and in preventing new HIV infections is becoming apparent," Sidibe added.
It found that the men and women who took a daily dose of the antiretroviral medicine tenofovir as oral pre-exposure prophylaxis (PrEP) were 49 per cent less likely to become infected with HIV than the volunteers who took the placebo.
"The results of this study are important and if used effectively in HIV programming could have a significant impact in protecting people who inject drugs from becoming infected with HIV,' Mr. Sidibe noted. The latest study complements results from several PrEP trials released over the past few years.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
